Fig. 1From: Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-α antagonists in management of ankylosing spondylitis: a dynamic population modelling studyMain components and simulation process of the patient-level model used for tracking a patient with ankylosing spondylitis. For more information, see Tran-Duy et al. [20]Back to article page